A Case of Bacterial Meningitis Due to Vancomycin Resistant Enterococcus Casseliflavus in a Nursling Child

Mehmet Bayraktar1, Suda Tekin2, Mehmet Resat Ceylan3, Tanfer Taspinar4
1Harran University, Medical Faculty, Department of Medical Microbiology, Sanliurfa, Turkey.
2Koç University, Medical Faculty, Department of Infectious Diseases and Clinical Microbiology, Sanliurfa, Turkey.
3Harran University, Medical Faculty, Department of Infectious Diseases and Clinical Microbiology, Sanliurfa, Turkey.
4Sanliurfa Children Hospital, Pediatric Clinic, Sanliurfa, Turkey

Abstract
Enterococcus casseliflavus is a rare pathogen that plays a role in various infections. It causes infections such as sepsis in humans. In adults, these are usually vancomycin resistant cases. We present a rare case of vancomycin-resistant E. casseliflavus meningitis in a 17-months-old girl who has been successfully treated with linezolid. The patient completely recovered after fourteen days of linezolid treatment. Vancomycin-resistant E. casseliflavus may be a potential pathogenic cause of meningitis in children with good clinical outcome by linezolid treatment. Linezolid therapy should be considered in children cases when vancomycin therapy failed.

Keywords: Enterococcus casseliflavus, Meningitis, Pediatrics

Öz

Anahtar kelimeler: Enterococcus casseliflavus, Menenjit, Pediatri

Harran Üniversitesi Tip Fakültesi Dergisi / Journal of Harran University Medical Faculty
INTRODUCTION
Enterococcus spp. are primarily found in the water, soil and food stuffs. Enterococcus fecalis and Enterococcus faecium are main human pathogens (1,2). Other enterococcal species such as E. casseliflavus and E. gallinarum are motile enterococci causing serious invasive infections in 1-2% of all enterococcal infections especially in older patients (2,3). Despite its rarity, the importance of this pathogen has increased recently since it was implicated in infections in immunocompromised patients, and it displays intrinsic low level resistance to vancomycin and some strains show high level resistance to aminoglycosides (4). The aim of the present report is to present a case of meningitis caused by E. casseliflavus in a child.

CASE REPORT
A 17 months old female nursling child with fever, coughing and irritability was administered to Sanliurfa Pediatric Hospital, Sanliurfa, Turkey. There was no history of previous illness or an underlying disease. Physical examination revealed fever (38.2 °C), pulse rate 128/min, blood pressure 110/75 mmHg and respiratory rate 24/min. Oropharynx was hyperemic with oral aphts and gingivitis. Laboratory examination showed haemoglobin (HB) 10 g/dL, haematocrit of 32.3 %, white blood cell (WBC) count 16100/mm³ (predominance of neutrophils 72% and 28% other leukocytes) platelet count 244000/mm³, ESR 20 mm/h and C-reactive protein (CRP) 1438 mg/L. Serum biochemical tests were within normal limits. Combined therapy of ceftriaxone and amikacin was started empirically and continued for 4 days. Oral lesions improved after the antibiotic therapy. However, body temperature and CRP remained high. So, lumbar puncture was performed on the 4th day. Examination of CSF revealed WBC count 1600 cells/ml (95% polymorphonuclear leukocytes PNL), protein level 1438 mg/L (normally 150-450 mg/L) and glucose concentration 14.6 mg/dL (simultaneous blood glucose 140 mg/dL). Direct Gram stain of CSF showed Gram positive cocci and PNL. The general condition of the patient was deteriorating. Therefore, we discontinued the treatment and a new empirical antibiotic treatment was started with vancomycin and imipenem. The organism yielded yellow colonies on both blood and Muller-Hinton agar. It was also positive for bile-esculin test and growth in 6.5% NaCl. The organism was identified as E. casseliflavus using Vitek 2 Compact (BioMerieux, France). The isolate was sensitive to ampicillin (MIC,2µg/ml), erythromycin (MIC,0.5µg/ml), imipenem (MIC,1µg/ml), ciprofloxacin (MIC,0.5µg/ml), moxifloxacin (MIC,0.25µg/ml), teicoplanin (MIC,0.5µg/ml) and gentamicin (MIC,0.1µg/ml). It was resistant to clindamycin (MIC,8µg/ml), trimethoprim/sulfamethoxazole (MIC,10µg/ml), tetracycline (MIC,16µg/ml), high dose of streptomycin (MIC,2000µg/ml), and vancomycin (MIC,4µg/ml). Accordingly to antimicrobial test report, combined vancomycin and imipenem was discontinued after three days post therapy. Sulbactam ampicillin was started at a dose of (3x100 mg/kg/day). Fever was still present and no improvement in patient’s condition was seen within 48 hours of treatment. Thereafter, treatment was changed to intravenous linezolid (10 mg/kg/day). Forty eight hours after therapy, fever disappeared and the patient’s general condition improved. On the 4th day of linezolid treatment, blood WBC count declined to 10000 cells /mL and CRP was 5.6mg/dL. Lumbar puncture was repeated and it showed no leukocytes and absence of bacterial growth. Other CSF values were normal. Therapy continued daily for 14 days. The patient recovered completely and discharged from the hospital.
DISCUSSION
Enterococcal meningitis is an uncommon disease. *E. faecalis* and *E. faecium* are responsible for most of enterococcal infections in humans and rarely involved in bacterial meningitis. They account for 0.3–4% of the reported cases of bacterial meningitis (5). Motile enterococci such as *E. gallinarum* and *E. casseliflavus* are unusual etiological agents of bacterial meningitis. Several studies have demonstrated that motile enterococci colonize the gastrointestinal tracts of both hospitalized individuals and nonhospitalized healthy ones (6). They are usually implicated in bacteremia cases (2,6-8). They are naturally resistant to vancomycin and best treated with linezolid and daptomycin (3,6). Review the literature, there were three cases of *E. gallinarum* meningitis and two cases of *E. casseliflavus* meningitis (9,10). The first case of *E. casseliflavus* meningitis was in an elderly woman. Our case report describes the clinical features and outcome of *E. casseliflavus* in pediatric meningitis. Our patient was a hospitalized child in whom a tentative diagnosis of pneumonia was made on the hospitalization day. On the hospitalization day 4, his condition deteriorated again. *E. casseliflavus* was isolated from the CSF. Although there was no clear focus for *E. casseliflavus* in our case, we believe that the source of infection could have been the patient’s own gastrointestinal flora. Antimicrobial therapy with various agents such as cephalosporins and vancomycin may play a role in increasing colonization with these organisms (11). However, treatment should be regulated according to the results of sensitivity tests. VanC genotype is responsible for low intrinsic resistance to vancomycin in *E. casseliflavus* and VanC-2/3 ligase is specific for it (12,13). A case of enterococcal meningitis caused by *E. casseliflavus* was successfully treated with meropenem and ampicillin-sulbactam (9). Similar to other studies, our isolate was also susceptible to ampicillin. Ampicillin-sulbactam therapy was administered. Lack of clinical improvement or poor response as well as the patient’s clinical deterioration, prompted us to change the treatment to linezolid, the first member of oxazolidone. The difficulty in treating *E. casseliflavus* meningitis may be due to drug kinetics and microbial drug resistance. On the second day after the initiation of treatment, both the patient’s clinical and laboratory findings gradually improved. On the 18th day, the patient completely recovered. Linezolid penetrates into the CSF and it has also good activity against both *E. faecium* and non-*E. faecium* species (*E. casseliflavus*) (3,8,14).

The present report stresses the need for clinicians to be aware of *E. casseliflavus* meningitis since the organism possesses an intrinsic low level vancomycin resistance and VanC phenotype. Proper management of infection by this rare organism warrants correct identification and sensitivity testing of such an isolate. Our attention should be drawn to serious infections caused by this motile organism even in patients without severe underlying disease or immunocompromised status. As a result, *E. casseliflavus* may cause rare central nervous system infections. The increasing resistance to treatment should be considered over time. A favourable outcome was observed with intravenous linezolid in this case report and it should be considered as a treatment option for similar cases. To our knowledge, our case is the first case in a pediatric patient and the third case of *E. casseliflavus* meningitis reported.

REFERENCES


